C-reactive protein levels and outcomes after statin therapy

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Statins are known to reduce low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) levels.
• The clinical impact of statin-induced CRP reduction on patient outcomes remains to be fully elucidated.

Purpose of the Study:

• To investigate the relationship between achieved LDL cholesterol and CRP levels post-statin therapy and the risk of recurrent cardiovascular events.
• To determine the relative importance of LDL cholesterol versus CRP levels in predicting clinical outcomes in patients with acute coronary syndromes.

Main Methods:

• A cohort of 3745 patients with acute coronary syndromes were analyzed.
• The study evaluated the association between post-treatment LDL cholesterol and CRP levels with recurrent myocardial infarction or coronary death.
• Patients received either atorvastatin 80 mg or pravastatin 40 mg daily.

Main Results:

• Lower achieved LDL cholesterol (<70 mg/dL) was associated with reduced event rates (2.7 vs. 4.0 events per 100 person-years, P=0.008).
• Similarly, lower achieved CRP levels (<2 mg/L) correlated with significantly lower event rates (2.8 vs. 3.9 events per 100 person-years, P=0.006), irrespective of LDL cholesterol levels.
• The combination of LDL cholesterol <70 mg/dL and CRP <1 mg/L yielded the lowest event rate (1.9 per 100 person-years).

Conclusions:

• Achieving low CRP levels after statin therapy is independently associated with improved clinical outcomes.
• Monitoring CRP levels, in addition to LDL cholesterol, should be incorporated into strategies for cardiovascular risk management.
• The choice of statin therapy was less critical than achieving target LDL and CRP levels for patient outcomes.